Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Milan Fiala has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autologous macrophages stimulated by epoxides of polyunsaturated fatty acids and protected by inhibitors of soluble epoxide hydrolase or cGAS/STING pathway repair amyloid‐β pathology in the Alzheimer’s disease (AD) brain

    by Milan Fiala, Julian Whitelegge, Bruce D. Hammock, Santosh Kesari

    Background: Brain accumulation of amyloid‐ß1‐42 (Aß) in plaques and neurons is the cause of AD neuropathology that is opposed by autologous monocyte/macrophages (MMs) in health but this defense fails in AD.Method: RNAseq, immunochemistry of the brain, immunofluorescence, and confocal microscopy of macrophages.Result: In the AD brain, MMs shuttle Aß from parenchyma to vessels, which develop vasculitis, causing amyloid‐related imaging abnormalities (ARIAs). AD patients’ MMs are inflammatory and lack enzymes in energy, and chaperones for unfolded protein response (UPR) and Aß degradation. Epoxides of polyunsaturated fatty acids (EpFAs), in combination with the inhibitors of soluble epoxide hydrolase (sEH) TPPU or EC5026 or the cGAS/STING pathway, regulate in macrophages in a homeostatic fashion Aβ‐degrading enzymes, inflammatory cytokines, and unfolded protein response (UPR) transcripts, and recover a pro‐resolution macrophage phenotype. The repaired macrophages display increased phagocytosis of FITC‐ Aß at 2 hours and increased degradation of Aβ at 24 hours. Others showed in a mouse model that restoration of cellular bioenergetics through inhibition of the prostaglandin E2 (PGE2) receptor 4 (EP4R) signaling restored cognition.Conclusion: Inhibiting macrophage inflammation by the sEH receptor inhibitors TPPU and EC5026 or the STING inhibitor H‐151 in AD macrophages could restore cognition in AD patients.

  • Open Access

    Inhibitors of Soluble Epoxide Hydrolase and cGAS-STING Pathway Repair the Defects in Macrophage Clearance of Amyloid-β Underlying Vascular Complications of Alzheimer’s Disease Patients

    by Milan Fiala, Bruce D. Hammock, Sung-Hee Hwang, Julian Whitelegge, Karolina Elżbieta Kaczor-Urbanowicz, Andrzej Urbanowicz, Santosh Kesari

    Alzheimer’s disease (AD) and the therapies of AD with anti-amyloid1-42 (Aβ) monoclonal antibodies are associated with the vascular complications of brain edema, hemorrhage, and cerebral amyloid angiopathy (CAA) termed amyloid-related imaging abnormalities (ARIAs). The neuropathology of normal and AD brains demonstrates that monocyte/macrophages (MMs) are critical in successful brain clearance in healthy brain by up-loading, transporting, and degrading Aβ but fail degradation and clearance in AD patients by releasing Aβ into vessels at the blood-brain barrier, causing vasculitis and ARIAs. The naturally-formed epoxides (EpFAs) of polyunsaturated fatty acids (PUFA’s), including arachidonic, docosahexaenoic, and eicosapentaenoic fatty acids, may repair degradation of Aβ by regulating Aβ-degrading enzymes, inflammatory cytokines, and unfolded protein response (UPR) to endoplasmic reticulum stress in a homeostatic fashion. EpFAs are, however, degraded by the soluble epoxide hydrolase enzyme (sEH) but are protected by the sEH inhibitor (sEHI) TPPU. In the cultures of AD patients’ macrophages, TPPU with the epoxide EEQ, and the cGAS/STING inhibitor H-151 increased uptake of Aβ at 2 hours and degradation of Aβ at 24 hours. In conclusion, the soluble epoxide hydrolase inhibitor TPPU with omega-3 fatty acids and the cGAS/STING inhibitor H-151 increase Aβ uptake and degradation in macrophages of AD patients, and potentially enhancing Aβ clearance in the AD brain.

  • Open Access

    The Role of Endoplasmic Reticulum Stress and Its Regulation in the Progression of Neurological and Infectious Diseases

    by Mary Dover, Michael Kishek, Miranda Eddins, Naneeta Desar, Ketema Paul, Milan Fiala

  • Open Access

    Therapy of autoimmune inflammation in sporadic amyotrophic lateral sclerosis: Dimethyl fumarate and H‐151 downregulate inflammatory cytokines in the cGAS‐STING pathway

    by Kurosh Zamiri, Santosh Kesari, Ketema Paul, Sung Hee Hwang, Bruce Hammock, Karolina Elżbieta Kaczor‐Urbanowicz, Andrzej Urbanowicz, Lucy Gao, Julian Whitelegge, Milan Fiala

    In sporadic amyotrophic lateral sclerosis (sALS), IL‐17A‐ and granzyme‐positive cytotoxic T lymphocytes (CTL), IL‐17A‐positive mast cells, and inflammatory macrophages invade the brain and spinal cord. In some patients, the disease starts following a trauma or a severe infection. We examined cytokines and cytokine regulators over the disease course and found that, since the early stages, peripheral blood mononuclear cells (PBMC) exhibit increased expression of inflammatory cytokines IL‐12A , IFN‐γ , and TNF‐α , as well as granzymes and the transcription factors STAT3 and STAT4 . In later stages, PBMCs upregulated the autoimmunity‐associated cytokines IL‐23A and IL‐17B , and the chemokines CXCL9 and CXCL10 , which attract CTL and monocytes into the central nervous system. The inflammation is fueled by the downregulation of IL‐10 , TGFβ , and the inhibitory T‐cell co‐receptors CTLA4 , LAG3 , and PD‐1 , and, in vitro, by stimulation with the ligand PD‐L1. We investigated in two sALS patients the regulation of the macrophage transcriptome by dimethyl fumarate (DMF), a drug approved against multiple sclerosis and psoriasis, and the cyclic GMP‐AMP synthase/stimulator of interferon genes (cGAS/STING) pathway inhibitor H‐151. Both DMF and H‐151 downregulated the expression of granzymes and the pro‐inflammatory cytokines IL‐1β , IL‐6 , IL‐15 , IL‐23A , a nd IFN‐γ , and induced a pro‐resolution macrophage phenotype. The eicosanoid epoxyeicosatrienoic acids (EET) from arachidonic acid was anti‐inflammatory in synergy with DMF. H‐151 and DMF are thus candidate drugs targeting the inflammation and autoimmunity in sALS via modulation of the NFκB and cGAS/STING pathways.


  • Open Access

    Polyunsaturated Fatty Acids Mend Macrophage Transcriptome, Glycome, and Phenotype in the Patients with Neurodegenerative Diseases, Including Alzheimer’s Disease

    by Mary Dover, Taylor Moseley, Adrienne Biskaduros, Mousumi Paulchakrabarti, Sung Hee Hwang, Bruce Hammock, Biswa Choudhury, Karolina Elżbieta Kaczor-Urbanowicz, Andrzej Urbanowicz, Marco Morselli, et al.

    Background: Macrophages of healthy subjects have a pro-resolution phenotype, upload amyloid-β (Aβ) into endosomes, and degrade Aβ, whereas macrophages of patients with Alzheimer’s disease (AD) generally have a pro-inflammatory phenotype and lack energy for brain clearance of Aβ. Objective: To clarify the pathogenesis of sporadic AD and therapeutic effects of polyunsaturated fatty acids (PUFA) with vitamins B and D and antioxidants on monocyte/macrophage (MM) migration in the AD brain, MM transcripts in energy and Aβ degradation, MM glycome, and macrophage clearance of Aβ. Methods: We followed for 31.3 months (mean) ten PUFA-supplemented neurodegenerative patients: 3 with subjective cognitive impairment (SCI), 2 with mild cognitive impairment (MCI), 3 MCI/vascular cognitive impairment, 2 with dementia with Lewy bodies, and 7 non-supplemented caregivers. We examined: monocyte migration in the brain and a blood-brain barrier model by immunochemistry and electron microscopy; macrophage transcriptome by RNAseq; macrophage glycome by N-glycan profiling and LTQ-Orbitrap mass spectrometry; and macrophage phenotype and phagocytosis by immunofluorescence. Results: MM invade Aβ plaques, upload but do not degrade Aβ, and release Aβ into vessels, which develop cerebrovascular amyloid angiopathy (CAA); PUFA upregulate energy and Aβ degradation enzyme transcripts in macrophages; PUFA enhance sialylated N-glycans in macrophages; PUFA reduce oxidative stress and increase pro-resolution MM phenotype, mitochondrial membrane potential, and Aβ phagocytosis (p < 0.001). Conclusion: Macrophages of SCI, MCI, and AD patients have interrelated defects in the transcriptome, glycome, Aβ phagocytosis, and Aβ degradation. PUFA mend macrophage transcriptome, enrich glycome, enhance Aβ clearance, and benefit the cognition of early-stage AD patients.


  • Open Access

    The Role of M1- and M2-Type Macrophages in Neurological and Infectious Diseases

    by Mary Dover, Michael Kishek, Miranda Eddins, Naneeta Desar, Milan Fiala

    Macrophages have a critical role in the outcome of neurological diseases, including neurodegenerative, autoimmune, vascular and microbial diseases. Macrophage role ranges from beneficial to pathogenic depending upon genetics, other components of innate and adaptive immunity, lifestyle and macrophage targets: aggregated molecules or bacterial and viral pathogens. Macrophages are attracted by chemokines to migrate into the brain and remove or inactivate pathogenic molecules. In the patients with neurodegenerative diseases, macrophages target aggregated molecules, amyloid-β1–42 (Aβ) and P-tau in Alzheimer’s disease (AD), and superoxide dismutase-1 (SOD-1) in amyotrophic lateral sclerosis (ALS), but also have autoimmune targets. In AD and ALS patients, macrophages in the pro-resolution M1M2 state are adapted to brain clearance and homeostasis, whereas in the proinflammatory M1 state are modulate to an anti-viral and antibacterial role, which may be associated with collateral damage to tissues. In HIV-1 and CoV2 viral infections, macrophages in M1 state are anti-viral but also pathogenic through inflammatory damage to the heart and the brain. In neurodegenerative diseases, the natural substances polyunsaturated fatty acids (PUFA), vitamins B and D, energy molecules, and flavonoids have beneficial effects on macrophage transcriptome and functions for brain clearance, but the effects are complex and depend on many variables.


  • Omega‐3 fatty acid add‐on nutritional immunotherapy delays progression to dementia in MCI patients on cholinesterase therapy

    by Milan Fiala

    Background: Cholinesterase inhibitor (CI) drugs have cognitive benefits for one year but are not disease modifying. Omega‐3 fatty acids (omega‐3) with anti‐oxidants and resveratrol increase transcription of energy molecules, enhance phagocytosis of amyloid‐β (Aβ), increase monocyte/macrophages (MM) clearance of Aβ in the AD brain, and may be disease modifying.Method: We test cognition by MMSE, energy in peripheral blood mononuclear cells (PBMC) and macrophages using a) single cell RNA‐seq, b) respirometry in the Seahorse Analyzer; c) phagocytosis of fluorescent Aβ and P‐tau. We study glycans in PBMC using nanoLC/ESI‐QTOF‐MS system.Result: We enrolled into the study patients with cognitive problems who had been failing CI therapy according to neurologists and caregivers. We diagnosed study patients by neurological testing and imaging: 8 as subjective cognitive impairment (SCI), 7 as MCI, 1 as fronto‐temporal dementia (FTD), 2 as vascular cognitive impairment (VCI), and 3 as dementia with Lewy bodies (DLB). In the study, the patients added supplementation by omega‐3 fatty acid drink with anti‐oxidants and resveratrol (Smartfish) to CI. On these therapies, MCI patients maintained MCI status for >1 to 4.5 years and all improved Aβ immunity and activities of daily living in short term. The ω‐3 –supplemented MCI patients up regulated in vivo and in vitro glycolytic and TCA cycle enzymes and NAD synthesis enzyme NAMPT and increased Aβ phagocytosis. DLB and FTD patients progressed to dementia in 1 to 2 years, despite omega‐3.Conclusion: MCI patients have energy deficiency in macrophages and other immune cells. Omega‐3 provide ox‐phos energy for immune clearance of Aβ and neuronal homeostasis around the clock, thereby delaying progression to dementia.

  • Open Access

    Omega‐3 fatty acids increase OXPHOS energy for immune therapy of Alzheimer disease patients

    by Yik Chai Charles Lau, Jessica Aliyah Ding, Aracely Simental, Hayk Mirzoyan, William Lee, Graciel Diamante, Ingrid Cely, Michelle Tran, Marco Morselli, Johnny Dang, et al.

    Sporadic late‐onset Alzheimer disease (LOAD) preceded by mild cognitive impairment (MCI) is the most common type of dementia. Long‐term studies of immunity to pathogenic amyloid‐β (Aβ) in LOAD are lacking. Innate immunity of LOAD patients is malfunctioning in phagocytosis and degradation of Aβ and LOAD patients’ macrophage transcriptome and metabolome are deregulated. We previously showed omega‐3 fatty acid (ω‐3)‐mediated repair of unfolded protein response and here we show much broader transcriptomic effects. ω‐3 treatment in vitro and ω‐3 supplementation by the drink Smartfish (SMF) in vivo increased the transcripts of the genes and pathways of immunity, glycolysis, tricarboxylic acid cycle, OX‐PHOS, nicotinamide dinucleotide (NAD + ) synthesis, and reversed the defects in Aβ phagocytosis. In both peripheral blood mononuclear cells (PBMC) and macrophages, ω‐3 increased ATP‐linked oxygen consumption rate (OCR) and ω‐3 with carnitine was superior to ω‐3. ω‐3 treatment in vitro and supplementation by the ω‐3 drink SMF in vivo rescued macrophage phagocytosis when glycolysis or glycosylation were blocked. ω‐3 provide flexible energy for immune clearance of the brain throughout the diurnal cycle, even in hypo‐ or hyper‐glycemia. In certain LOAD patients, ω‐3 may delay progression to dementia.


  • Omega-3 Fatty Acids Increase Amyloid-β Immunity, Energy, and Circadian Rhythm for Cognitive Protection of Alzheimer’s Disease Patients Beyond Cholinesterase Inhibitors

    by Milan Fiala, Yik Chai Charles Lau, Anthony Aghajani, Sneha Bhargava, Eli Aminpour, Karolina Elżbieta Kaczor-Urbanowicz, Hayk Mirzoyan, India Nichols, Meng-Wei Ko, Marco Morselli, et al.

    Background: The cholinesterase inhibitor therapeutics (CI) approved for use in Alzheimer’s disease (AD) are palliative for a limited time. Objective: To examine the outcome of AD patients with add-on therapy of the omega-3 fatty acid drink Smartfish. Methods: We performed a prospective study using Mini-Mental State Examination, amyloid-β (Aβ) phagocytosis blood assay, and RNA-seq of peripheral blood mononuclear cells in 28 neurodegenerative patients who had failed their therapies, including 8 subjective cognitive impairment (SCI), 8 mild cognitive impairment (MCI), 2 AD dementia, 1 frontotemporal dementia (FTD), 2 vascular cognitive impairment, and 3 dementia with Lewy bodies (DLB) patients. Results: MCI, FTD, and DLB patients patients volunteered for the addition of a ω-3 fatty acid drink Smartfish protected by anti-oxidants to failing CI therapy. On this therapy, all MCI patients improved in the first year energy transcripts, Aβ phagocytosis, cognition, and activities of daily living; in the long term, they remained in MCI status two to 4.5 years. All FTD and DLB patients rapidly progressed to dementia. On in vivo or in vitro ω-3 treatments, peripheral blood mononuclear cells of MCI patients upregulated energy enzymes for glycolysis and citric acid cycle, as well as the anti-inflammatory circadian genes CLOCK and ARNTL2. Conclusion: Add-on ω-3 therapy to CI may delay dementia in certain patients who had failed single CI therapy.


  • Open Access

    Immunotherapy of Mild Cognitive Impairment by ω -3 Supplementation: Why Are Amyloid-β Antibodies and ω -3 Not Working in Clinical Trials?

    by Milan Fiala, Lucas Restrepo, Matteo Pellegrini

    This article reviews the basic tenets of a clinical approach to effective immunotherapy of Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). Although one randomized controlled study in early MCI patients by fish-derived omega-3 fatty acids ( ω-3) showed slowing of disease progression, large clinical trials with different products have failed to show cognitive effects. Macrophages of healthy subjects phagocytize and degrade amyloid-β 1 - 42 (Aβ) in the brain tissues, whereas macrophages of patients with AD and MCI are functionally defective. ω-3 and ω-3-derived specialized proresolving mediators (SPMs), such as resolvin D1, have powerful biochemical and immunological effects, which may repair the functions of MCI patients’ macrophages in the brain’s clearance of Aβ. Unfortunately, ω-3 products on the market have a variable quality. Nutritional supplementation with a combination drink called Smartfish with an emulsion of ω-3 and other fatty acids, antioxidants, 1,25-dihydroxy vitamin D3, and resveratrol improved the innate immune system of MCI patients by modulation of macrophage type to the pro-phagocytic M1-M2 type with an effective unfolded protein response against endoplasmic reticulum stress. Some MCI patients maintained their initial cognitive status for three years on Smartfish supplementation. Future randomized clinical trials should investigate the immune effects of ω-3, 1,25-dihydroxy vitamin D3, and SPMs on macrophage type, function, and biochemistry in parallel with cognitive effects.